Roy S. Herbst, MD, PhD | Authors

August 01, 2018

Roy S. Herbst, MD, PhD, Yale Cancer Center, discusses the use of combination immunotherapy for the treatment of lung cancer.

April 05, 2017

Roy S. Herbst, MD, PhD, professor of Medicine, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses an ongoing trial at Yale Cancer Center exploring the use of positive messaging in smoking cessation counseling for lung cancer during the AACR Annual Meeting.

December 08, 2016

Roy. S. Herbst, MD, PhD, professor of Medicine (Medical Oncology), professor of Pharmacology, chief of Medical Oncology, Yale Cancer Center, discusses the phase III KEYNOTE-010 study, in which pembrolizumab provided superior overall survival over docetaxel in patients with previously treated, PD-L1-expressing advanced non-small cell lung cancer. He discussed these results during an interview at the IASLC 17th World Conference on Lung Cancer.

October 06, 2016

Roy S. Herbst, MD, PhD, discusses the immunotherapy combinations under investigation in NSCLC during the IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology.